Kodiak Sciences

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 111

Market Cap: $138.9M

Website

Introduction: Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Clinical Trials

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE

Phase 3

Not yet recruiting

Conditions: Macular Edema Secondary to Inflammation

Interventions: Drug: KSI-101
Other: Sham Comparator

First Posted Date: 2025-05-30

Last Posted Date: 2025-05-30

Lead Sponsor: Kodiak Sciences Inc

Target Recruit Count: 150

Registration Number: NCT06996080

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

Phase 3

Not yet recruiting

Conditions: Macular Edema Secondary to Inflammation

Interventions: Drug: KSI-101
Other: Sham Comparator

First Posted Date: 2025-05-25

Last Posted Date: 2025-05-25

Lead Sponsor: Kodiak Sciences Inc

Target Recruit Count: 150

Registration Number: NCT06990399

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

Phase 3

Recruiting

Conditions: Wet Age-related Macular Degeneration

Interventions: Drug: Tarcocimab tedromer
Drug: Tabirafusp tedromer
Drug: Aflibercept

First Posted Date: 2024-08-16

Last Posted Date: 2025-06-11

Lead Sponsor: Kodiak Sciences Inc

Target Recruit Count: 675

Registration Number: NCT06556368

Locations: 🇺🇸
Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸
Retina Macula Institute of Arizona, Scottsdale, Arizona, United States
🇺🇸
Retina Associates SW, Tucson, Arizona, United States

and more 59 locations

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

Phase 3

Active, not recruiting

Conditions: Diabetic Retinopathy

Interventions: Drug: Tarcocimab
Other: Sham injection

First Posted Date: 2024-02-21

Last Posted Date: 2025-03-30

Lead Sponsor: Kodiak Sciences Inc

Target Recruit Count: 255

Registration Number: NCT06270836

Locations: 🇺🇸
Retina Associates SW, Tucson, Arizona, United States
🇺🇸
Retina Consultants of Orange County, Fullerton, California, United States
🇺🇸
Global Research Management, Inc. - Lugene Eye Institute, Glendale, California, United States

and more 34 locations

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)

Phase 3

Terminated

Conditions: Non-proliferative Diabetic Retinopathy

Interventions: Other: Sham injection
Drug: KSI-301

First Posted Date: 2021-10-04

Last Posted Date: 2024-04-11

Lead Sponsor: Kodiak Sciences Inc

Target Recruit Count: 253

Registration Number: NCT05066230

Locations: 🇺🇸
Retinal Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸
Retina Vitreous Associates, Beverly Hills, California, United States
🇺🇸
Retina Consultants of Orange County, Fullerton, California, United States

and more 58 locations

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

Phase 3

Completed

Conditions: Wet Age-related Macular Degeneration

Interventions: Drug: KSI-301
Drug: Aflibercept
Other: Sham Procedure

First Posted Date: 2021-07-15

Last Posted Date: 2024-07-03

Lead Sponsor: Kodiak Sciences Inc

Target Recruit Count: 557

Registration Number: NCT04964089

Locations: 🇺🇸
Retinal Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸
Northwest Arkansas Retina Associates, Springdale, Arkansas, United States
🇺🇸
California Retina Consultants, Bakersfield, California, United States

and more 63 locations

A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

Phase 3

Terminated

Conditions: Diabetic Macular Edema

Interventions: Drug: KSI-301
Drug: Aflibercept
Other: Sham Procedure

First Posted Date: 2020-11-02

Last Posted Date: 2024-08-22

Lead Sponsor: Kodiak Sciences Inc

Target Recruit Count: 460

Registration Number: NCT04611152

Locations: 🇺🇸
UCSD Jacobs Retina Center, La Jolla, California, United States
🇺🇸
Retina Consultants of Southern California, Redlands, California, United States
🇺🇸
California Retina Consultants, Santa Maria, California, United States

and more 72 locations

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

Phase 3

Terminated

Conditions: Diabetic Macular Edema

Interventions: Drug: KSI-301
Drug: Aflibercept
Other: Sham Procedure

First Posted Date: 2020-10-27

Last Posted Date: 2024-08-22

Lead Sponsor: Kodiak Sciences Inc

Target Recruit Count: 459

Registration Number: NCT04603937

Locations: 🇺🇸
Retinal Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸
Retina Vitreous Associates, Beverly Hills, California, United States
🇺🇸
Retina Consultants of Orange County, Fullerton, California, United States

and more 68 locations

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

Phase 3

Completed

Conditions: Macular Edema
Retinal Vein Occlusion

Interventions: Drug: KSI-301
Drug: Aflibercept
Other: Sham Procedure

First Posted Date: 2020-10-19

Last Posted Date: 2024-06-26

Lead Sponsor: Kodiak Sciences Inc

Target Recruit Count: 568

Registration Number: NCT04592419

Locations: 🇺🇸
Northwest Arkansas Retina Associates, Phoenix, Arizona, United States
🇺🇸
Retinal Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸
Retina Vitreous Associates, Beverly Hills, California, United States

and more 137 locations

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

Phase 2

Terminated

Conditions: Wet Macular Degeneration

Interventions: Drug: Aflibercept
Drug: KSI-301
Other: Sham Procedure

First Posted Date: 2019-08-08

Last Posted Date: 2024-07-18

Lead Sponsor: Kodiak Sciences Inc

Target Recruit Count: 559

Registration Number: NCT04049266

Locations: 🇺🇸
Retinal Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸
Northwest Arkansas Retina Associates, Springdale, Arkansas, United States
🇺🇸
California Retina Consultants, Santa Maria, California, United States

and more 70 locations

AI-Powered Research

Premium Access

Kodiak Sciences

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.